Achillion is a user of Twitter and maintains a corporate acccount using the screen name:@achillionpharma.
Achillion recognizes the importance of social media, including Twitter, and new communication channels that enable Achillion to engage in interactive discussion with the Company’s stakeholders. As a development-stage biopharmaceutical company, Achillion is committed to abide by the legal, ethical and regulatory standards applicable to the Company. By maintaining an active Twitter account, Achillion aims to responsibly interact with stakeholders.
Achillion may respond to questions and comments presented via Twitter when appropriate. Achillion may not be able to immediately respond to questions or comments, and responses, if any, may be limited in nature.
There may be questions and/or comments Achillion cannot address, including, but not limited to, questions related to non-public confidential information, proprietary information, financial matters, ongoing legal matters, regulatory issues and other aspects of Achillion’s business. Achillion will not respond to rumors, personal attacks, foul language, disparaging comments or topics that do not relate directly to Achillion.
Twitter accounts that Achillion follows or is followed by do not indicate an endorsement of the account owner or their products and services.
Achillion may provide links or references to external websites, not controlled by Achillion, as part of its Tweets. However, Achillion does not endorse or claim responsibility for the content of such other websites. Any links or references to such external websites are provided as merely a convenience to the users of the Twitter platform.
Achillion reserves all rights relating to the Achillion Twitter account (@achillionpharma) including, but not limited to, all rights to add, remove or modify any content or material posted on the account, discontinue the account, accept or reject those who may wish to follow the account and respond to, or refrain from responding to, any questions or comments addressed to the account.